Amendments to the Claims are reflected in the listing of the claims which begins on page 2 of this paper.

Remarks begin on page 7 of this paper.

Listing of the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Claims 1-21 (cancelled)

Claim 22 (currently amended): An isolated nucleic acid having at least 80% nucleic acid sequence identity to:

(a) a nucleic acid sequence encoding the polypeptide shown in Figure 32 (SEQ ID NO:83);

(b) a nucleic acid sequence encoding the polypeptide shown in Figure 32 (SEQ ID NO: 83), lacking its associated signal peptide;

(c) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO: 83);

(d) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO: 83), lacking its associated signal peptide;

(e) the nucleic acid sequence shown in Figure 31 (SEQ ID NO:82);

(f) the full-length coding sequence of the nucleic acid sequence shown in Figure 31 (SEQ ID NO:82); or

(g) the full-length-coding sequence of the cDNA deposited under ATCC accession number 209621;

wherein the polypeptide encoded by the nucleic acid is able to inhibit proliferation of stimulated T-lymphocytes.

Claim 23 (currently amended): The isolated nucleic acid of claim 22 having at least 85% nucleic acid sequence identity to:

(a) a nucleic acid sequence encoding the polypeptide shown in Figure 32 (SEQ ID NO:83);

(b) a nucleic acid sequence encoding the polypeptide shown in Figure 32 (SEQ ID NO: 83), lacking its associated signal peptide;

(c) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO: 83);

(d) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO: 83), lacking its associated signal peptide;

(e) the nucleic acid sequence shown in Figure 31 (SEQ ID NO:82);

(f) the full-length coding sequence of the nucleic acid sequence shown in Figure 31 (SEQ ID NO:82); or

(g) the full-length-coding sequence of the cDNA deposited under ATCC accession number 209621;

wherein the polypeptide encoded by the nucleic acid is able to inhibit proliferation of stimulated T-lymphocytes.

Claim 24 (currently amended): The isolated nucleic acid of Claim 22 having at least 90% nucleic acid sequence identity to:

(a) a nucleic acid sequence encoding the polypeptide shown in Figure 32 (SEQ ID NO:83);

(b) a nucleic acid sequence encoding the polypeptide shown in Figure 32 (SEQ ID NO: 83), lacking its associated signal peptide;

(c) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO: 83);

(d) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO: 83), lacking its associated signal peptide;

(e) the nucleic acid sequence shown in Figure 31 (SEQ ID NO:82);

(f) the full-length coding sequence of the nucleic acid sequence shown in Figure 31 (SEQ ID NO:82); or

(g) the full-length-coding sequence of the cDNA deposited under ATCC accession number 209621;

wherein the polypeptide encoded by the nucleic acid is able to inhibit proliferation of stimulated T-lymphocytes.

Claim 25 (currently amended): The isolated nucleic acid of Claim 22 having at least 95% nucleic acid sequence identity to:

(a) a nucleic acid sequence encoding the polypeptide shown in Figure 32 (SEQ ID NO:83);

(b) a nucleic acid sequence encoding the polypeptide shown in Figure 32 (SEQ ID NO: 83), lacking its associated signal peptide;

(c) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO: 83);

(d) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO: 83), lacking its associated signal peptide;

(e) the nucleic acid sequence shown in Figure 31 (SEQ ID NO:82);

(f) the full-length coding sequence of the nucleic acid sequence shown in Figure 31 (SEQ ID NO:82); or

(g) the full-length-coding sequence of the cDNA deposited under ATCC accession number 209621;

wherein the polypeptide encoded by the nucleic acid is able to inhibit proliferation of stimulated T-lymphocytes.

Claim 26 (currently amended): The isolated nucleic acid having at least 99% nucleic acid sequence identity to:

(a) a nucleic acid sequence encoding the polypeptide shown in Figure 32 (SEQ ID NO:83);

(b) a nucleic acid sequence encoding the polypeptide shown in Figure 32 (SEQ ID NO: 83), lacking its associated signal peptide;

(c) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO: 83);

(d) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO: 83), lacking its associated signal peptide;

(e) the nucleic acid sequence shown in Figure 31 (SEQ ID NO:82);

(f) the full-length coding sequence of the nucleic acid sequence shown in Figure 31 (SEQ ID NO:82); or

(g) the full-length-coding sequence of the cDNA deposited under ATCC accession number 209621;

wherein the polypeptide encoded by the nucleic acid is able to inhibit proliferation of stimulated T-lymphocytes.

Claim 27 (previously added): An isolated nucleic acid comprising:

(a) a nucleic acid sequence encoding the polypeptide shown in Figure 32 (SEQ ID NO:83);

(b) a nucleic acid sequence encoding the polypeptide shown in Figure 32 (SEQ ID NO: 83), lacking its associated signal peptide;

(c) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO: 83);

(d) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO: 83), lacking its associated signal peptide;

(e) the nucleic acid sequence shown in Figure 31 (SEQ ID NO:82);

(f) the full-length coding sequence of the nucleic acid sequence shown in Figure 31 (SEQ ID NO:82); or

(g) the full-length-coding sequence of the cDNA deposited under ATCC accession number 209621.

Claim 28 (previously added): The isolated nucleic acid of Claim 27 comprising a nucleic acid sequence encoding the polypeptide shown in Figure 32 (SEQ ID NO: 83).

Claim 29 (previously added): The isolated nucleic acid of Claim 27 comprising a nucleic acid sequence encoding the polypeptide shown in Figure 32 (SEQ ID NO: 83), lacking its associated signal peptide.

Claim 30 (previously added): The isolated nucleic acid of Claim 27 comprising a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO: 83).

Claim 31 (previously added): The isolated nucleic acid of Claim 27 comprising a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO: 83), lacking its associated signal peptide.

Claim 32 (previously added): The isolated nucleic acid sequence of Claim 27 comprising the nucleic acid sequence shown in Figure 31 (SEQ ID NO:82).

Claim 33 (previously added): The isolated nucleic acid sequence of Claim 27 comprising the full-length coding sequence of the nucleic acid sequence shown in Figure 31 (SEQ ID NO:82).

Claim 34 (previously added): The isolated nucleic acid sequence of Claim 27 comprising the full-length coding sequence of the cDNA deposited under ATCC accession number 209621.

Claim 35 (previously added): An isolated nucleic acid that hybridizes to:

(a) a nucleic acid sequence encoding the polypeptide shown in Figure 32 (SEQ ID NO:83);

(b) a nucleic acid sequence encoding the polypeptide shown in Figure 32 (SEQ ID NO: 83), lacking its associated signal peptide;

(c) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO: 83);

(d) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO: 83), lacking its associated signal peptide;

(e) the nucleic acid sequence shown in Figure 31 (SEQ ID NO:82);

(f) the full-length coding sequence of the nucleic acid sequence shown in Figure 31 (SEQ ID NO:82); or

(g) the full-length-coding sequence of the cDNA deposited under ATCC accession number 209621.

Claim 36 (previously added): The isolated nucleic acid of Claim 35, wherein said hybridization occurs under stringent conditions.

Claim 37 (previously added): The isolated nucleic acid of Claim 35 which is at least 10 nucleotides in length.

Claim 38 (previously added): A vector comprising the nucleic acid of Claim 22.

Claim 39 (previously added): The vector of Claim 38, wherein said nucleic acid is operably linked to control sequences recognized by a host cell transformed with the vector.

Claim 40 (previously added): A host cell comprising the vector of Claim 38.

Claim 41 (previously added): The host cell of Claim 40, wherein said cell is a CHO cell, an *E. coli* or a yeast cell.